Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catalyst Pharm Inc (CPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 252,740
  • Shares Outstanding, K 102,740
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,410 K
  • 36-Month Beta 2.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.12
  • Number of Estimates 5
  • High Estimate -0.08
  • Low Estimate -0.15
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.18 +12.84%
on 12/06/18
3.23 -23.84%
on 11/28/18
-0.41 (-14.29%)
since 11/13/18
3-Month
2.18 +12.84%
on 12/06/18
4.05 -39.26%
on 09/26/18
-0.74 (-23.13%)
since 09/13/18
52-Week
2.18 +12.84%
on 12/06/18
4.21 -41.57%
on 12/14/17
-1.69 (-40.72%)
since 12/13/17

Most Recent Stories

More News
Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sabre Corporation (NASDAQ:SABR),...

REGI : 25.62 (-0.85%)
APEN : 4.05 (-1.22%)
SABR : 23.90 (-4.36%)
LMNX : 26.43 (-1.89%)
PKD : 0.43 (-61.26%)
CPRX : 2.46 (+2.50%)
Catalyst (CPRX) Down 27.6% Since Last Earnings Report: Can It Rebound?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CPRX : 2.46 (+2.50%)
Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse(R) (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS)

-- U.S. launch scheduled for early in the first quarter of 2019

CPRX : 2.46 (+2.50%)
Catalyst's Firdapse Receives FDA Approval for Rare Disease

Catalyst's (CPRX) Firdapse gets FDA approval for the treatment of LEMS in adults.

MRK : 79.01 (+1.28%)
GILD : 67.35 (-1.16%)
CPRX : 2.46 (+2.50%)
BMY : 53.64 (+0.37%)
Today's Research Reports on Trending Tickers: Alliqua BioMedical and Catalyst Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / November 29, 2018 / Shares of Alliqua BioMedical more than doubled on Wednesday on news of a cannabis relatedspin off. Shares of Catalyst Pharmaceuticals also saw big gains...

ALQA : 2.13 (-7.99%)
CPRX : 2.46 (+2.50%)
FDA Approves Firdapse(R) (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)

- First evidenced-based medicine approved to treat LEMS

CPRX : 2.46 (+2.50%)
Catalyst Pharmaceuticals Announces Firdapse(R) (amifampridine) New Drug Application Continues Under Review

Catalyst Pharmaceuticals Inc. (Nasdaq:CPRX) today reports that no decision has yet been received from the Food and Drug Administration with respect to the company's new drug application for Firdapse. The...

CPRX : 2.46 (+2.50%)
Do Options Traders Know Something About Catalyst (CPRX) Stock We Don't?

Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.

CPRX : 2.46 (+2.50%)
Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update

Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.

MRK : 79.01 (+1.28%)
LLY : 114.86 (+0.45%)
CPRX : 2.46 (+2.50%)
BMY : 53.64 (+0.37%)
Catalyst Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update

Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow

CPRX : 2.46 (+2.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade CPRX with:

Business Summary

CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for...

See More

Key Turning Points

2nd Resistance Point 2.63
1st Resistance Point 2.54
Last Price 2.46
1st Support Level 2.37
2nd Support Level 2.29

See More

52-Week High 4.21
Fibonacci 61.8% 3.43
Fibonacci 50% 3.20
Fibonacci 38.2% 2.96
Last Price 2.46
52-Week Low 2.18

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar